{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"EVOLVE 1","nct_id":"NCT07075016","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evolve-1-nct07075016. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EVOLVE 1","arms":[{"description":"day 1-28 Placebo Treatment will be on a continuous 28-day cycle schedule continued until disease relapse, disease progression, development of unacceptable toxicity, death, withdrawal of subject or other protocol defined criteria for discontinuation (which ever comes first)","label":"Placebo comparator: Venetoclax-placebo","type":"PLACEBO_COMPARATOR"},{"description":"day 1-28 Venetoclax Treatment will be on a continuous 28-day cycle schedule continued until disease relapse, disease progression, development of unacceptable toxicity, death, withdrawal of subject or other protocol defined criteria for discontinuation (which ever comes first)","label":"Experimental: Venetoclax","type":"EXPERIMENTAL"}],"collaborators":["German-Austrian Acute Myeloid Leukemia Study Group","United Kingdom AML Research Network","Gruppo Italiano Malattie EMatologiche dell'Adulto","Swiss Group for Clinical Cancer Research (SAKK)","Danish Acute Leukemia Group","Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias","Nordic AML Group"],"completion_date":{"date":"2029-03","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia"],"enrollment":{"count":227,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Venetoclax 400","otherNames":[],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2025-08-19","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","official_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy","timeFrame":"12 months after inclusion of last AML patient"}],"references":[],"start_date":{"date":"2025-08-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","url":"https://clinicaltrials.gov/study/NCT07075016"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evolve-1-nct07075016"}